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Abstract A 12-year-old boy with tuberous sclerosis complex (TSC) presented with a large
retroperitoneal tumour. Exploratory surgery revealed an infiltrative tumour originating
from the pancreas, with local metastases to the lymph nodes. The histologal diagnosis was
a malignant islet cell tumour. Retrospectively measured pancreatic hormone levels,
however, were normal. A connection between the malignancy and TSC was demonstrated
by loss of heterozygosity of the TSC2 gene in the tumour. The primary mutation Q478X
in this patient was identified in exon 13 of the TSC2 gene on chromosome 16.
Conclusion Pancreatic islet cell tumours have been mainly associated with multiple
endocrine neoplasia syndrome type 1. In our case we demonstrate a direct relationship
of this tumour to tuberous sclerosis complex, in the absence of further signs of multiple
endocrine neoplasia syndrome type 1.
Key words Tuberous sclerosis complex á TSC2 gene á Loss of heterozygosity á Pancreas á
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Abbreviations LOH loss of heterozygosity á MEN-1 multiple endocrine neoplasia
syndrome type 1 á TSC tuberous sclerosis complex
Introduction
Tuberous sclerosis complex (TSC) is an autosomal
dominant neurocutaneous disorder, with a birth preva-
lence of 1:6,000–10,000 [10], characterized by the growth
of hamartomas that can appear in virtually any organ or
tissue. Diagnostic criteria most widely used are those of
Gomez [4]. The most frequently aected organs are skin,
brain, kidneys, eyes, and heart. About 50% of patients
with TSC present as new cases in their family (new
mutations). Small children often present with epilepsy
and mental retardation. Abdominal involvement in TSC
usually involves the kidneys with bilateral multiple renal
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cysts, often in combination with angiomyolipomas. The
frequency of renal involvement in TSC has been esti-
mated to be between 40% and 80% [4]; in a small
number of patients the liver and/or pancreas show
changes like those in the kidneys. Malignant degenera-
tion of these tumours and cysts is rare. Mutation in one
of two separate genes can cause TSC. Both these genes
have been isolated: TSC1 on chromosome 9q34.3 [12]
and TSC2 on chromosome 16p13.3 [2]. The clinical
picture of patients with TSC1 mutations or with TSC2
mutations is very similar, perhaps indistinguishable. In
principle, each family has a separate mutation, but re-
currence of a particular mutation in unrelated sibships
has been reported [12,15].
In this report we demonstrate the case of a young boy
with TSC, presenting with abdominal pain, caused by a
malignant pancreatic islet cell tumour. Mutation anal-
ysis in blood cells of the patient resulted in the identifi-
cation of the germ-line mutation in the TSC2 gene. The
involvement of the TSC2 gene in the aetiology of the
pancreatic tumour was shown by the demonstration of
allelic loss of the non mutated allele of the TSC2 gene in
tumour tissue.
Materials and methods
The surgical specimen was fixed for 24 h in 4% phosphate buered
formalin, 4 lm paran embedded sections were stained with ha-
ematoxylin and eosin. The used antibodies were directed against
chromogranin-A (polyclonal, DAKO), insulin (polyclonal,
DAKO), synaptophysin (monoclonal, Boehringer), gastrine (poly-
clonal, DAKO), islet amyloid polypeptide (gift from van Hulst [6]),
somatostatin (polyclonal, DAKO), glucagon (polyclonal, DAKO)
and MIB-1 (monoclonal, Immunotech). Subsequently streptavidin-
biotin-peroxidase staining was done. Immunohistochemical pro-
cedures were performed as described previously [14].
Primer sequences for direct sequence analysis of the 41 exons of
the TSC2 gene are available on request. PCR conditions for exon
13 for 100 ll volume were 10 mM Tris pH 8.3, 1.5 mM MgCl2,
50 mM KCl, 100 lM mix of each deoxynucleotide and 2 U of Taq
polymerase (Gibco BRL). For the amplification reaction of exon 13
thermal cycling conditions were 5 min at 94°C, followed by 35
cycles of 30 s at 94°C, 30 s at 55°C, 90 s at 72°C with a final
elongation of 5 min at 72°C. Cycle sequence reactions were per-
formed using the ABI prism dye primer cycle sequence ready re-
action kit (Perkin Elmer), gels were run on an ABI 377 automated
DNA sequencer.
Loss of heterozygosity (LOH) studies were initiated by com-
paring DNA from peripheral leucocytes and DNA from tumour
tissue, using markers D9S149 and D9S150 for the chromosome
9q34 TSC1 region [12], and KG8(intragenic in the PKD1 gene,
adjacent to the TSC2 gene) and 16AC2.5(D16S291) for the chro-
mosome 16p13 TSC2 region [2]. The LOH results were confirmed
by allele specific oligonucleotide hybridization analysis (sequences
available on request). Hybridization was performed at 37°C for 1 h,
filters were washed to 0.3 ´ SSC for 10 min at 37°C.
Case report
The patient was born in 1985 as the second child from healthy, non
consanguineous, parents. Pregnancy and delivery had been normal.
At 2 years a diagnosis of TSC was made on the basis of the pres-
ence of epilepsy, hypopigmented macules, mental retardation and
CT scan abnormalities characteristic of TSC: subependymal calci-
fied nodules, hypodense areas and left frontal atrophy. Ophthal-
mological examination and renal ultrasound were normal. By the
age of 7 years, he had facial angiofibromas, a fibrous forehead
plaque and ungual fibromas of the feet. At 9 years of age a large
angiomyolipoma of the right kidney was embolized (both kidneys
showed multiple smaller angiomyolipomas), and he underwent
surgery for a subependymal giant cell astrocytoma, with placement
of a ventriculoperitoneal shunt. Some months afterwards he had
abdominal pains. Abdominal ultrasound showed no visible changes
in his pre-existing renal TSC lesions. He had normal glucose levels,
erythrocyte sedimentation rate, and liver and renal function pa-
rameters. The possibility of a psychosomatic component to his
complaints was considered and a period of observation was al-
lowed. Subsequently, an abdominal CT scan was made, showing a
highly vascularized retroperitoneal tumour, growing from either
the left kidney, stomach or pancreas. Needle biopsy was considered
to be too risky. Explorative surgery proved the tumour to be of
pancreatic origin, with infiltrative growth into the colon and
stomach. Macroscopic subtotal resection was done, including the
directly neighbouring lymph nodes. Post operative recovery was
without complications.
Both his parents had been completely screened for TSC in the
past and had shown no signs of the disease.
Results
Pathology showed an islet cell tumour of the tail of the
pancreas (maximum length 9.5 cm), with invasive growth
into the posterior wall of the stomach and transverse
colon (Fig. 1 A,B). Three of the resected lymph nodes
showed metastases. Immunohistochemical staining was
positive for the neuroendocrine markers synaptophysin
and gastrine, and b-cell marker islet amyloid polypeptide,
negative for insulin and somatostatin. Parts of the tumour
were positive for chromogranin-A (a probable precursor
for regulatory proteins), glucagon and monoclonal anti-
body MIB-1 (a marker for cell proliferation). Retro-
spectively, glucagon and glucose levels were determined
in pre-operatively stored frozen plasma and were normal.
The tumour thus appeared to have been non-hormone
producing. Complete clinical screening of the patient for
other endocrine neoplasias was negative, making a diag-
nosis of multiple endocrine neoplasia syndrome type 1
(MEN-1) improbable.
DNA analysis for LOH in the tumour of either TSC
gene, using both chromosome 9 and 16 markers, showed
LOH of chromosome 16 with both TSC2 markers, not
with TSC1 markers (Fig. 2). The primary, germ-line
mutation in the TSC2 gene appeared to be a nucleotide
substitutionC into T at position 1450 in exon 13 (Q478X).
The LOH result was confirmed by allele specific oligo-
nucleotide hybridization analysis for the mutation,
showing that it was the normal, wild type allele that was
lost in the pancreatic tumour (Fig. 3). The mutation was
absent in DNA isolated from peripheral leucocytes of the
parents and is therefore a de novo mutation.
Discussion
We present a mentally retarded boy with tuberous scle-
rosis who developed an unexpected malignant pancreatic
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tumour, with infiltrative growth and local metastases to
the lymph nodes. Since radical excision was not possible,
follow up by regular CT scan will be done, as recurrence is
possible. The tumour was classified as a non-hormone
producing islet cell tumour, the boy did not show clinical
signs of a hormonal imbalance. Neuroendocrine tumours
in children are found in MEN-1 syndrome, which has
been mapped to chromosome 11. Screening for other
neuroendocrine tumours showed no other manifestations
of a possible co-existing MEN-1 syndrome. In MEN tu-
mours loss of chromosome 16p13 has not been described.
To our knowledge, no other reports on malignant pan-
creatic tumours in children with TSC have been pub-
lished. If aected, the pancreas usually shows cysts and
angiomyolipomas. Islet cell tumours and gastrinoma
have been incidentally reported in adult TSC patients
[1, 7, 11].
Malignancies do sometimes arise in association with
tuberous sclerosis [3]. LOH has been reported in non
metastasizing hamartomas of TSC patients [5]. At
present it is unknown how the relatively rare transition
from benign hamartoma to metastasizing malignant
tumour should be viewed. Little is known about the
interactions between the TSC1 and TSC2 gene products,
called hamartin and tuberin respectively [13]. The dem-
onstration of loss of the wild type TSC-2 allele in a ne-
uroendocrine pancreatic tumour of this TSC patient
strongly suggests a role for TSC2 as a tumour suppres-
sor gene in its aetiology, in line with the proposed tu-
mour suppression function of tuberin [5]. This loss of the
non mutated allele, or ‘second hit’ is considered to be a
decisive step in tumourigenesis [8]. Mutation analysis
resulted in the identification of the Q478X germ-line
Fig. 1 A Low magnification (42´, chromogranin-A) to demonstrate
the infiltrative growth of the islet cell tumour of the pancreas in a 12-
year-old tuberous sclerosis patient. Note a similar staining with
chromogranin-A of normal pancreatic islet cells (arrow) and tumour
cells. B (inset) High magnification (500´, H & E) of the tumour cells.
Note the mild degree of nuclear pleomorphism and the occurrence of
binucleate tumour cells (arrowhead )
Fig. 2 Loss of heterozygosity (LOH) studies of blood (B) versus
pancreas tumour (T ) DNA of the index patient with tuberous
sclerosis. For chromosome 16 (left) markers KG8 and 16AC2.5
clearly show partial loss of one allele (arrows) in DNA isolated from
tumour (T) versus blood cells (B). For chromosome 9, markers
D9S149 and D9S150 show no loss. (Although the overall signal in
blood for D9S149 is reduced, the relative ratio of the alleles 1 and 2
remains unchanged)
Fig. 3 Demonstration of the Q478X mutation in exon 13 of the TSC2
gene in the patients blood (black square) and tumour tissue (T) by
allele specific oligonucleotide hybridization. [N the normal allele,
which is also present in the parents (left two dots), M mutated allele.]
The relative intensities of the normal versus the mutated signal are
clearly reversed in the tumour tissue, indicating LOH of the wild type
TSC2 allele
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mutation or ‘first hit’ in the patient, likely to produce a
severely truncated tuberin protein, instable and/or in-
active, from that allele. A naturally occurring rat strain
with a germ-line insertion in the TSC2 gene is the ‘Eker
rat’, which is prone to develop renal carcinoma. In vitro,
tumour growth can be inhibited by introducing an active
TSC2 gene into cultured tumour cells of this rat [9],
supporting the hypothesis that the TSC2 gene is a tu-
mour suppressor gene.
Our findings show that the TSC2 gene can be in-
volved in tumours that are not specifically associated
with TSC, and might play a more general role in the
suppression of tumour growth in dierent kinds of tis-
sues.
Acknowledgements We would like to thank Prof. Dr H. Galjaard
and the Foundation of Clinical Genetics for their continuous
support, and A.M.P. Tempelaars and P.L.G. Bakker for their
technical assistance. This project was sponsored by the Dutch
Praevention Fund, grant no 28–1723–1.
References
1. Davoren PM, Epstein MT (1992) Insulinoma complicating
tuberous sclerosis. J Neurol Neurosurg Psychiatr 55:1209
2. The European Chromosome 16 Tuberous Sclerosis Consortium
(1993) Identification and characterization of the tuberous
sclerosis gene on chromosome 16. Cell 75:1305–1315
3. Gomez MR (1988) ‘‘Tuberous sclerosis.’’ 2nd edn. Raven
Press, New York
4. Gomez MR (1991) Phenotypes of the tuberous sclerosis com-
plex with a revision of diagnostic criteria. Ann NY Acad Sci
615:1–7
5. Green AJ, Smith M, Yates JRW (1994) Loss of heterozygosity
on chromosome 16p13.3 in hamartomas from tuberous scle-
rosis patients. Nat Genet 6:193–196
6. Hulst KL van, Hoppener JWM, Berends MHJ, et al (1994)
Characterization of antibodies against human islet amyloid
polypeptide (IAPP/amylin) and its C-terminal flanking poly-
peptide (C-proIAPP). Eur J Endocrinol 130 [Suppl 2]:196
7. Kim H, Kerr A, Morehouse H (1995) The association between
tuberous sclerosis and insulinoma. Am J Neuroradiol 16:1543–
1544
8. Knudson AG (1971) Mutation and cancer: statistical study of
retinoblastoma. Proc Natl Acad Sci 68: 820–823
9. Orimoto K, Tsuchiya H, Kobayashi T, Matsuda T, Hino O
(1996) Suppression of the neoplastic phenotype by replacement
of the TSC2 gene in Eker rat renal carcinoma cells. Biochem
Biophys Res Comm 219:70–75
10. Osborne JP, Fryer A, Webb D (1991) Epidemiology of tuber-
ous sclerosis. Ann NY Acad Sci 615:125–127
11. Schwarzkopf G, Pfisterer J (1993): Metastasierendes Gastrinom
und der Tuberoese Sklerose Komplex. Zentralbl Pathol
139:477–481
12. Slegtenhorst M van, Hoogt R de, Hermans C, et al (1997)
Identification of the tuberous sclerosis gene TSC1 on chro-
mosome 9q34. Science 277: 805–808
13. Slegtenhorst M van, Nellist M, Nagelkerken B, et al (1998):
Interaction between hamartin and tuberin, the TSC1 and TSC2
gene products. Hum Mol Gen 7:1053–1057
14. Verbeek BS, Vroom TM, Adriaansen-Slot SS, et al (1996) C-
SRC protein expression is increased in human breast cancer.
An immunohistochemical and biochemical analysis. J Pathol
180:383–388
15. Verhoef S, Vrtel R, Bakker L, Stolte-Dijkstra I, Nellist M,
Begeer JH, Zaremba J, Jozwiak S, Tempelaars AMP,
Lindhout D, Halley DJJ, Ouweland AMW van den (1998)
Recurrent mutation 4882delTT in the GAP-related domain
of the tuberous sclerosis TSC2 gene. Hum Mutat
[Suppl1]:S85–S87
287
